OPS-2071

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameOPS-2071
Drug Alias NameOPS-2071
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Quinolone antibiotics
Mechanisms of ActionTopoisomerase IV inhibitorsBacterial DNA gyrase inhibitors
TargetsTopoisomerase IVBacterial DNA gyrase
Therapy Area/IndicationsIrritable Bowel SyndromeCrohn DiseaseEnteritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporePoland +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKanae Co Ltd (Kobe Plant)Otsuka Pharmaceutical Co LtdOtsuka Pharmaceutical Co.,Ltd Second Tokushima Factory +[4] 
Inactive CompaniesOtsuka Pharmaceutical Development & Commercialization IncKorea Otsuka Pharmaceutical Co Ltd
Active IndicationsIrritable Bowel Syndrome
Inactive IndicationsCrohn DiseaseEnteritis

Other Information

ATC CodeN/A
Related LinksN/A